ClinicalTrials.gg
CompletedNCT06116890Updated Oct 14, 2026

Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration

A Phase 2 interventional study of KHK4951 and Aflibercept Injection in Neovascular Age-Related Macular Degeneration (nAMD), sponsored by Kyowa Kirin Co., Ltd.. Completed at 84 sites in 4 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Kyowa Kirin Co., Ltd. · Phase 2, Interventional, and Treatment

How we know

Updated Oct 14, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 645 studies in Macular Degeneration with a site in United States — 84 open to participants now, 128 under way, 24 of them phase 3. Macular Degeneration · United States.

Enrollment
123rd of 491
170 · median 55
Started
2024
with 23 others
Phase 2
138 of 645
14 open now
Registered
557th of 645
by date

Among the 645 studies in Macular Degeneration with a site in United States, this one is the 123rd largest by enrollment of the 491 interventional ones that give a count, is one of 24 that started in 2024, is one of 138 in phase 2, and was the 557th registered.

Macular Degeneration

1,461 studies on the registry are indexed under Macular Degeneration; 237 are open to participants now.

Browse Macular Degeneration studies →

Open to participants now

84 of the 645 studies in Macular Degeneration with a site in United States are open now. Recruiting first, the newest first:

79 more — sign in →

All 84 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 167 Macular Degeneration studies recruiting now, 118 (71%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 36 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 645 studies in Macular Degeneration with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with nAMD.

03

Conditions studied

  • Neovascular Age-Related Macular Degeneration (nAMD)
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary written to participate in the study
  • Active subfoveal MNV (any subtype) or juxtafoveal/extrafoveal MNV secondary to AMD with a subfoveal component related to the MNV activity in the study eye as assessed by FA (evidence of leakage) or SD-OCT (presence of fluid) judged by the central reading center at screening
  • BCVA ETDRS letter score of 78 letters to 35 letters in the study eye as measured by the ETDRS visual acuity chart at screening
  • CST ≥ 450 μm at screening

Exclusion criteria

Exclusion Criteria:

  • Subretinal hemorrhage, fibrosis, or atrophy of > 50% of the total lesion area and/or that involves the fovea in the study eye
  • Uncontrolled glaucoma in the study eye
  • Aphakia or pseudophakia with AC-IOL in the study eye
  • Active intraocular inflammation in the study eye
  • Any current ocular condition for which visual acuity loss would not improve from resolution of macular edema in the study eye
  • History of rhegmatogenous retinal detachment in the study eye
  • Any current or history of ocular disease other than nAMD in the study eye that may confound assessment of the macula or affect central vision
  • History of the following therapies in the study eye:

    • History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD
    • Prior treatment PDT with Visudyne®, external-beam radiation therapy, transpupillary thermotherapy, or panretinal photocoagulation
    • Periocular or intraocular (sub-Tenon or IVT) within 12 weeks prior to Day 1
    • Previous intraocular device implantation except PC-IOL
    • Previous laser (any type) to the macular area
    • Previous treatment with IVT anti-VEGF drugs other than ranibizumab, bevacizumab, aflibercept 2 mg, and their biosimilars;
    • Treatment with ranibizumab, bevacizumab, aflibercept 2 mg, or their biosimilars within 12 weeks prior to Day 1. Previously treated patients who received these medications more than 12 weeks prior to Day 1 can be enrolled, but the patients should be diagnosed with nAMD within 3 years prior to Day 1
  • Any current or history of endophthalmitis in either eye
  • History of idiopathic or -associated uveitis in either eye
  • Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
170 participants (actual)

Study arms

  • Experimental
    Arm A

    KHK4951 High dose

    Drug: KHK4951 · Drug: Aflibercept Injection

  • Experimental
    Arm B

    KHK4951 Middle dose

    Drug: KHK4951 · Drug: Aflibercept Injection

  • Experimental
    Arm C

    KHK4951 Low dose

    Drug: KHK4951 · Drug: Aflibercept Injection

Interventions

  • KHK4951 eye drop for 44 weeks until end of the trial

  • DrugAfliberceptStudies of AfliberceptAflibercept pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Intravitreal injection (IVT) of aflibercept will be given as specified in the protocol

06

What researchers measure

Primary outcomes

  1. Reduction of 15 or more letters in BCVA (Best corrected visual acuity) as measured by ETDRS visual acuity chart from baseline

    Time frame: For 44 weeks until the end of the trial

Secondary outcomes

  1. The number of aflibercept IVT

    Time frame: For 44 weeks until the end of the trial

  2. Change from baseline in SHRM as measured by SD-OCT

    Time frame: 44 weeks

  3. Change from baseline in retinal morphology as measured by SD-OCT

    Time frame: 44 weeks

  4. Change from baseline in MNV lesion area and total MNV leakage area as measured by FA

    Time frame: 44 Weeks

Other outcomes

  1. Number of participants with adverse events

    Time frame: For 44 weeks until the end of the trial

  2. Serum KHK4951 concentration

    Time frame: 44 Weeks

07

Study locations

84 sites
  • Barnet Dulaney Perkins Eye Center - Phoenix
    Mesa, Arizona 85206, United States
  • Retina Associates Southwest, P.C.
    Tucson, Arizona 85710, United States
  • Win Retina
    Arcadia, California 91006, United States
  • Retina Vitreous Associates Medical Group
    Beverly Hills, California 90211, United States
  • The Retina Partners
    Encino, California 91436, United States
  • Salehi Retina Institute, Inc
    Huntington Beach, California 92647, United States
  • Payam Amini
    Pasadena, California 91107, United States
  • Retina Consultants of Southern CO
    Colorado Springs, Colorado 80909, United States
  • Blue Ocean Clinical Research West
    Clearwater, Florida 33761, United States
  • Florida Eye Associates
    Melbourne, Florida 32901, United States
  • Eye Associates of Pinellas
    Pinellas Park, Florida 33782, United States
  • Ft. Lauderdale Eye Institute
    Plantation, Florida 33324, United States
  • Retina Vitreous Associates of Florida - Saint Petersburg
    St. Petersburg, Florida 33711, United States
  • Southern Vitreoretinal Associates
    Tallahassee, Florida 32308, United States
  • Center for Retina and Macular Disease - Ophthalmology
    Winter Haven, Florida 33880, United States
  • Southeast Retina Center
    Augusta, Georgia 30909, United States
  • Massachusetts Eye and Ear
    Boston, Massachusetts 02114, United States
  • Associated Retinal Consultants (ARC) P.C. - Opthalmology
    Royal Oak, Michigan 48073, United States
  • Sierra Eye Associates
    Reno, Nevada 89502, United States
  • Retina Center of New Jersey
    Bloomfield, New Jersey 07003, United States
  • Vision Research Center Eye Associates of New Mexico
    Albuquerque, New Mexico 87109, United States
  • Retina Vitreous Surgeons of Central NY, PC
    Liverpool, New York 13088, United States
  • Ophthalmic Consultants of Long Island
    Oceanside, New York 11572, United States
  • Retina Vitreous Center in Edmond Oklahoma
    Edmond, Oklahoma 73013, United States
  • Eye Health Northwest
    Portland, Oregon 97225, United States
  • Eye Care Specialists
    Kingston, Pennsylvania 18704, United States
  • Charleston Neuroscience Institute (RCA Network Site)
    Ladson, South Carolina 29456, United States
  • Black Hills Regional Eye Institute - Ophthalmology
    Rapid City, South Dakota 57701, United States
  • Charles Retina Institute
    Germantown, Tennessee 38138, United States
  • Retina Research Institute of Texas
    Abilene, Texas 79606, United States
  • Austin Retina Associates - Ophthalmology/Retina (RCA Network site)
    Austin, Texas 78705, United States
  • Austin Clinical Research, LLC
    Austin, Texas 78750, United States
  • Retina Consultants of Texas
    Bellaire, Texas 77401, United States
  • Texas Retina Associates
    Fort Worth, Texas 76104, United States
  • Retinal Consultants of Texas- San Antonio (RCA Network site)
    San Antonio, Texas 78240, United States
  • Retina Consultants of Texas (RCA Network Site)
    The Woodlands, Texas 77384, United States
  • Strategic Clinical Research Group, LLC
    Willow Park, Texas 76087, United States
  • Retina Group of Washington
    Fairfax, Virginia 22031, United States
  • Eye Clinic Albury Wodonga
    Albury, New South Wales 2640, Australia
  • Marsden Eye Specialists
    Parramatta, New South Wales, Australia
  • Strathfield Retina Clinic
    Strathfield, New South Wales, Australia
  • Sydney Eye Hospital
    Sydney, New South Wales, Australia
  • Adelaide Eye and Retina Centre
    Adelaide, South Australia 5000, Australia
  • Centre for Eye Research Australia
    East Melbourne, Victoria 3002, Australia
  • Aichi Medical University Hospital - Ophthalmology
    Nagakute, Aichi-ken 480-1195, Japan
  • MIYAKE Eye Hospital
    Nagoya, Aichi-ken 462-0825, Japan
  • Toho University Medical Center Sakura Hospital
    Sakura, Chiba 285-8741, Japan
  • Matsuyama Red Cross Hospital
    Matsuyama, Ehime 790-8524, Japan
  • Hayashi Eye Hospital - Ophthalmology
    Fukuoka, Fukuoka 812-0011, Japan
  • Kurume University Hospital
    Kurume, Fukuoka 830-0011, Japan
  • Minamitohoku Eye Clinic
    Kōriyama, Fukushima 963-8563, Japan
  • Caress Sapporo Tokeidai Memorial Hospital
    Sapporo, Hokkaido 060-0031, Japan
  • Kobe University Hospital - Ophthalmology
    Kobe, Hyôgo 650-0017, Japan
  • Kozawa Eye Hospital and Diabetes Center
    Mito, Ibaraki 310-0845, Japan
  • Kagawa University Hospital
    Kita-gun, Kanagawa 761-0793, Japan
  • Shinshu University Hospital - Ophthalmology
    Matsumoto, Nagano 390-8621, Japan
  • Nara Medical University Hospital - Ophthalmology
    Kashihara, Nara 634-8522, Japan
  • University of the Ryukyus Hospital
    Nakagami-gun, Okinawa 903-0215, Japan
  • Kansai Medical University Medical Center
    Hirakata, Osaka 660-0892, Japan
  • Kindai University Hospital
    Sayama, Osaka 577-8502, Japan
  • Jichi Medical University Hospital
    Shimotsuke, Tochigi 329-0498, Japan
  • The University of Tokyo Hospital
    Bunkyō, Tokyo 113-8655, Japan
  • Nihon University Hospital
    Chiyoda City, Tokyo 101-8309, Japan
  • Tokyo Medical University Hachioji Medical Center
    Hachiōji, Tokyo 193-0998, Japan
  • Tokyo Medical Center
    Meguro City, Tokyo 152-8902, Japan
  • Keio University Hospital - Ophthalmology
    Shinjuku, Tôkyô 160-8582, Japan
  • Fukushima Medical University Hospital - Ophthalmology
    Fukushima, 960-1295, Japan
  • Rakuwakai Otowa Hospital
    Kyoto, 607-8062, Japan
  • Okayama University Hospital - Ophthalmology
    Okayama, 700-8558, Japan
  • Saitama Red Cross Hospital
    Saitama, 330-8553, Japan
  • Osaka Metropolitan University Hospital
    Osaka, Ôsaka 545-0051, Japan
  • Keimyung University Dongsan Hospital
    Daegu, Dalseo-gu 42601, South Korea
  • Seoul National University Bundang Hospital
    Seongnam, Gyeonggido, South Korea
  • CHA Bundang Medical Center, CHA University
    Seongnam-si, Gyeonggido 13496, South Korea
  • Yeungnam University Hospital
    Daegu, Nam-gu 42415, South Korea
  • Gachon University Gil Medical Center
    Incheon, Namdong-gu 21565, South Korea
  • Kyung Hee University Hospital
    Seoul, Seoul Teugbyeolsi 02447, South Korea
  • Korea University Anam Hospital
    Seoul, Seoul Teugbyeolsi 02841, South Korea
  • Seoul National University Hospital
    Seoul, Seoul Teugbyeolsi 03080, South Korea
  • Severance Hospital, Yonsei University Health System
    Seoul, Seoul Teugbyeolsi 03722, South Korea
  • Asan Medical Center
    Seoul, Seoul Teugbyeolsi 05505, South Korea
  • Samsung Medical Center
    Seoul, Seoul Teugbyeolsi 06351, South Korea
  • The Catholic University of Korea, Seoul St. Mary's Hospital
    Seoul, Seoul Teugbyeolsi 06591, South Korea
  • Kim Eye Hospital
    Seoul, Seoul Teugbyeolsi 07301, South Korea
08

References and documents

Individual participant data

Plan to share: Yes — The datasets generated and/or analyzed during the study sponsored by Kyowa Kirin will be available in the Vivli repository, https://vivli.org/ourmember/kyowakirin/ as long as conditions of data disclosure specified in the policy section of the Vivli website are satisfied.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2024 to primary completion in Jun 2026, 28 months.

Of 66 industry-sponsored phase 2 interventional studies under Macular Degeneration, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 28 months is above that.

Counting every sponsor, half of 83 studies reached it within 24 months; a quarter within 16 and three quarters within 35.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Aug 2026 → Jun 2026 and completion Sep 2026 → Jul 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2023
First posted
Nov 3, 2023
StartActual
Jan 31, 2024
Primary completionActual
Jun 3, 2026was Aug 2026
CompletionActual
Jul 1, 2026was Sep 2026
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Oct 14, 2026
Primary completion
Aug 31, 2026→Jun 3, 2026 (actual)
Oct 14, 2026
Study completion
Sep 30, 2026→Jul 1, 2026 (actual)
Oct 14, 2026
Enrollment
180 (estimated)→170 (actual)
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Active, not recruiting→Completed
    Primary completion Aug 31, 2026→Jun 3, 2026 (now actual)
    Study completion Sep 30, 2026→Jul 1, 2026 (now actual)
    Enrollment 180 (estimated)→170 (actual)
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06116890
Responsible party
Sponsor
First posted
Nov 3, 2023
Start date
Jan 31, 2024
Primary completion
Jun 3, 2026
Completion
Jul 1, 2026
Last update
Oct 14, 2026

Study contacts

Sotaro Takigawa
study director · Kyowa Kirin Co., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: KHK4951

Start the discussion